CCR 20th anniversary commentary: Preclinical study of proteasome inhibitor bortezomib in head and neck cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25733706.
- Also identified by DOI 10.1158/1078-0432.CCR-14-2550 and PMC identifier 4351792.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a study published in the May 1, 2001, issue of Clinical Cancer Research, Sunwoo and colleagues provided evidence for proteasome inhibition of NF-κB and tumorigenesis, supporting early-phase clinical trials in solid malignancies of the upper aerodigestive tract. Subsequent clinical studies uncovered a dichotomy of responses in patients with hematopoietic and solid malignancies, and the mechanisms of resistance.
Medical subject headings
- Antineoplastic Agents
- Boronic Acids
- Multienzyme Complexes
- NF-kappa B
- Pyrazines